Motley Fool
Why Editas Medicine Beat the Market on Monday
Editas Medicine (NASDAQ: EDIT) got a spoonful of good medicine on Monday that gave its shares a healthy lift; ultimately, the stock closed the day more than 4.4% higher. Lee’s new bullishness on the company, which utilizes gene-editing technology to develop medications, is due to several positive factors. Finally, in his research note, Lee touted the company’s “scarcity value as a relatively unencumbered CRISPR-Cas platform company making [it] attractive as a potential partner or a target.”